Table 3 Multiple linear regression analysis for the prediction of CSI score reduction at 6 months (n = 86).
From: Efficacy of galcanezumab in migraine central sensitization
Variables | Regression coefficient estimate | CI 95% | p value |
|---|---|---|---|
ASC-12 score reduction | 0.531 | 0.049; 1.012 | 0.0312† |
Headache days/month reduction | 0.150 | − 0.179; 0.478 | 0.3672 |
Headache days of at least moderate severity/month reduction | 0.343 | − 0.016; 0.702 | 0.0612 |
Days with acute medication use/month reduction | − 0.252 | − 0.666; 0.162 | 0.2286 |
MIDAS score reduction | 0.012 | − 0.034; 0.058 | 0.6144 |
